Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Joshua D. Lambert; Ross O. Meyers; Barbara N. Timmermann; Robert T. Dorr

doi:10.1016/S0378-4347(00)00592-2

Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Joshua D. Lambert, Ross O. Meyers, Barbara N. Timmermann, Robert T. Dorr

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

Original language	English (US)
Pages (from-to)	85-90
Number of pages	6
Journal	Journal of Chromatography B: Biomedical Sciences and Applications
Volume	754
Issue number	1
DOIs	https://doi.org/10.1016/S0378-4347(00)00592-2
State	Published - Apr 15 2001
Externally published	Yes

Keywords

Nordihydroguaiaretic acid

ASJC Scopus subject areas

General Chemistry

Access to Document

10.1016/S0378-4347(00)00592-2

Cite this

@article{905e5e8fc6b04b7a8c7bb09661e0324c,

title = "Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse",

abstract = "Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.",

keywords = "Nordihydroguaiaretic acid",

author = "Lambert, {Joshua D.} and Meyers, {Ross O.} and Timmermann, {Barbara N.} and Dorr, {Robert T.}",

note = "Funding Information: The authors thank Dr. Bhashyam Iyengar for technical assistance and Dr. Steven P. Stratton and Katherine Watt for their critical evaluation of this manuscript. This study was partially funded by the ICBG “Bioactive Agents from Dryland Plants of Latin America” grant 401TW00316 from the National Institutes of Health (NIH) and National Science Foundation (NSF) (to B.N.T.); and the Arizona Disease Control Research Commission (ADCRC) grant 20009.",

year = "2001",

month = apr,

day = "15",

doi = "10.1016/S0378-4347(00)00592-2",

language = "English (US)",

volume = "754",

pages = "85--90",

journal = "Journal of Chromatography B: Biomedical Sciences and Applications",

issn = "1387-2273",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

AU - Lambert, Joshua D.

AU - Meyers, Ross O.

AU - Timmermann, Barbara N.

AU - Dorr, Robert T.

N1 - Funding Information: The authors thank Dr. Bhashyam Iyengar for technical assistance and Dr. Steven P. Stratton and Katherine Watt for their critical evaluation of this manuscript. This study was partially funded by the ICBG “Bioactive Agents from Dryland Plants of Latin America” grant 401TW00316 from the National Institutes of Health (NIH) and National Science Foundation (NSF) (to B.N.T.); and the Arizona Disease Control Research Commission (ADCRC) grant 20009.

PY - 2001/4/15

Y1 - 2001/4/15

N2 - Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

AB - Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model. Despite these findings, there have been no reports on the pharmacokinetics of NDGA. A reverse-phase high-performance liquid chromatography (HPLC) method was developed to detect NDGA in mouse plasma. The limit of detection of this method was 0.5 μg/ml. Administration of NDGA (50 mg/kg, i.v.) to mice resulted in a peak plasma concentration of 14.7 μg/ml. The terminal half-life of NDGA was 135.0 min with a clearance of 201.9 ml/min·kg.

KW - Nordihydroguaiaretic acid

UR - http://www.scopus.com/inward/record.url?scp=0035871898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035871898&partnerID=8YFLogxK

U2 - 10.1016/S0378-4347(00)00592-2

DO - 10.1016/S0378-4347(00)00592-2

M3 - Article

C2 - 11318430

AN - SCOPUS:0035871898

SN - 1387-2273

VL - 754

SP - 85

EP - 90

JO - Journal of Chromatography B: Biomedical Sciences and Applications

JF - Journal of Chromatography B: Biomedical Sciences and Applications

IS - 1

ER -

Pharmacokinetic analysis by high-performance liquid chromatography of intravenous nordihydroguaiaretic acid in the mouse

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this